II. General
III. Characteristics
- Conditions associated with High Estrogenic Activity
- Breast tenderness or engorgement
- Headaches
- Moodiness
- Weight Gain
- Heavy Menses
- Dysmenorrhea
- Conditions associated with Low Estrogenic Activity
- Break-through bleeding in first 9 days of cycle
- Break-through bleeding throughout month
- Menses too light
IV. Progestins with significant Estrogenic Activity
- Estrogen activity based on Ethinyl Estradiol ug/day
- Ethinyl estadiol (100): High reference
- Norethynodrel (8.3): No anti-Estrogen effect
- Ethynodiol Diacetate (3.4)
- Norethindrone (0.25): Low reference
V. Oral Contraceptive Estrogenic Activity (low to high)
- Estrogen activity based on Ethinyl Estradiol ug/day
- Loestrin 1.5/30 (Norethindrone Acetate): 14
- Estrostep (Norethindrone Acetate): 16
- Alesse (Levonorgestrel): 17
- Loestrin 1/20 (Norethindrone Acetate): 19
- Demulen 1/35 (Ethynodiol Diacetate): 19
- Nordette (Levonorgestrel): 25
- Lo-Ovral (Norgestrel): 25
- Triphasil (Levonorgestrel): 28
- Ortho-Cept or Desogen (Desogestrel): 30
- Ortho-Cyclen (Norgestimate): 35
- Ortho Tri-Cyclen (Norgestimate): 35
- Ortho-Novum 1/35 (Norethindrone): 38
- Modicon (Norethindrone): 42
- Ortho-Novum 777 (Norethindrone): 48
VI. References
- Cerel-Suhl (1999) Am Fam Physician 60(7):2073 [PubMed]
- Speroff (1993) Obstet Gynecol 81:1034-47 [PubMed]
- Dickey (1998) Managing Contraceptive Pill Patients